BITTERZ
Today (November 1), on behalf of Bitterz LLC (Hinds Building, Kingstown, St. Vincent and the Grenadines), we are pleased to announce that our global crypto exchange Bitterz in Japan will start to provide services to our customers in China, Hong Kong and Taiwan.
To celebrate the grand opening, we are currently offering $50 worth of bitcoins to all customers who open a new account (free of charge).
We hope that you will enjoy the experience of trading with our Japanese crypto exchange with these bitcoins.
Bitterz Official Website
https://bitterz.com/refs/top/10457
▪ Main features of Bitterz
1. A safe environment to continue trading
Bitterz is a completely Japanese crypto exchange, which is rare among global exchanges.
We offer a trading environment suitable for accumulating wealth, with a leverage of 200 times at most, a zero-cut system, and a reliable support system.
2. All the developers are Japanese
Bitterz's system development team is all Japanese and was formerly a group of engineers from a large, privately held company.
3. MT5: a specialized tool in cryptocurrency
With the fast response of MT5, we have achieved a stress-free trading environment.
You won't miss the trading timing even in the rapidly changing cryptocurrency market.
4. A highly secured trading environment
We have 24-hour-monitoring for dealing and security, a cold wallet to protect your holdings, and a two-step authentication system to prevent unauthorized logins, creating a highly secure trading environment.
Your cryptocurrency holdings are insured; with a multi-sig cold wallet, your holdings can only be transferred under multiple administrators’ approval.
Most of your holdings will be managed in the cold wallet, as we plan to store several days of withdrawals in the hot wallet.
5. Reliable support system
We offer the fastest support in the industry with native staffs from China and Taiwan to provide you with a secure trading environment.
6. Demo account for trading experience
You can experience cryptocurrency trading in the same environment as real trading without using your own money.
This is a great option for those who want a risk-free trading experience and who want to see how easy it is to use the tools in advance.
7. A reassuring zero-cut system
We have adopted a zero-cut system, where even in case of unexpected loss, there is no additional deposit in excess of your holdings, so you can trade proactively without worries.
8. Withdrawal (transfer) fees are practically free forever
There are many exchanges that don't charge a withdrawal (transfer) fee, but most of them require you to pay a mining fee.
Of course, we will never charge you a fee for withdrawal.
In addition, in order not to burden our clients with mining fees, we pay you back with MT5 bonus credit, which makes withdrawal (transfer) fees practically free.
9. Enrichment of campaigns
We aim to provide some kind of campaign at all times throughout the year.
Now, to celebrate the grand opening, we are currently offering $50 worth of bitcoins to all customers who open a new account (free of charge).
For more information, please visit the official website below.
Bitterz Official Website
https://bitterz.com/refs/top/10457
View source version on businesswire.com: https://www.businesswire.com/news/home/20201101005003/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aspect Announces CEO Leadership Transition and New Independent Board7.1.2026 00:13:00 CET | Press release
Aspect, a leading provider of cloud-based workforce management solutions, has announced a leadership transition, including the appointment of Jeff Kupietzky as Interim Chief Executive Officer and the formation of a new independent Board of Directors, marking an important next chapter for the company. As part of this transition, Darryl Kelly will step down as Chief Executive Officer and transition into a Strategic Advisor role, effective January 1, 2026. Darryl led Aspect through a pivotal period of transformation, helping reposition the business, refine its vision, and reinvigorate its innovation and execution. The company and its stakeholders thank Darryl for his leadership and contributions during a period of meaningful change. With Darryl continuing as Strategic Advisor, the organization retains continuity for employees, customers, and stakeholders. “Aspect is starting a new season, building upon the strong foundation we’ve created together,” said Darryl Kelly. “This transition is a
Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients6.1.2026 21:00:00 CET | Press release
Brenus Pharma, a clinical stage biotechnology company unlocking the immune system in vivo to fight solid tumors, announced the successful completion of the first dose levels in its ongoing first-in-human study. The multi-center, open-label trial (NCT06934538) is a phase Ia/Ib study designed to evaluate safety, tolerability and preliminary clinical activity of STC-10101 in a first line setting. It will include in vivo analysis of immune and tumor dynamics during dose escalation of treatment and cohort extension to patients with unresectable locally advanced (stage IIIC, T4b) or unresectable metastatic (stage IV) MSS2 colorectal cancer (CRC). Early findings indicate that the first dose levels have been successfully completed with good overall tolerance and no-dose-limiting toxicities observed to date. “We are pleased to report that the safety profile observed to date is good and consistent with our expectations with no DLT,” said Paul Bravetti, CEO of Brenus Pharma. “Moreover, preliminar
SPIE, the International Society for Optics and Photonics, Announces Its 2026 Fellows6.1.2026 20:35:00 CET | Press release
The Society is welcoming 40 new Fellow Members from across the globe SPIE, the international society for optics and photonics, welcomes 40 Members as new Fellows of the Society in the 2026 cohort. They join their Fellow Member colleagues in being honored for their excellent technical achievements, as well as for their substantial service to the optics and photonics community and to SPIE. Fellows are Members of the Society who have made significant scientific and technical contributions in the multidisciplinary fields of optics, photonics, and imaging. Since the Society's inception in 1955, more than 1,800 SPIE Members have become Fellows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106630672/en/ SPIE, the international society for optics and photonics, announces its 2026 Fellows This year’s inductees are high-profile leaders in academia, industry, and government, many of whom are particularly prominent in their support
Chemelex Adds Electric Heat Trace Group Ltd.’s SmartTrace Monitoring Platform to its Heat Tracing Portfolio6.1.2026 20:00:00 CET | Press release
Chemelex, a global leader in electric thermal and sensing solutions, today announced the successful completion of its acquisition of substantially all the assets and ongoing operations of Electric Heat Trace Group Ltd. (EHT Group), headquartered in Ontario, Canada. This strategic move marks an exciting start to the new year and reinforces Chemelex’s commitment to delivering smarter, data-driven solutions for industrial heat trace systems. EHT Group is a recognized innovator in heat trace management, offering advanced software, integrated controller solutions, wireless communication modules, and comprehensive field services. Its flagship platform, SmartTrace, is a robust solution available in both cloud-based and on-premises deployments that enables predictive maintenance, minimizes downtime, and provides secure remote monitoring—helping customers achieve greater reliability and operational efficiency. This endeavor will help Chemelex support greater operational efficiencies for our cus
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA6.1.2026 19:30:00 CET | Press release
Combination therapy showed compelling survival and disease control compared to current standard, regardless of PD-L1 statusHigh GEA burden in Asia, where BeOne holds ZIIHERA rights, signals potential broad patient impactResults to be presented as a Late-Breaking Abstract Oral Presentation at ASCO GI on January 8, 2026 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). These data, including the first interim overall survival (OS) analysis, will be presented as a Late-Breaking Abstract Oral Presentation (#LBA285) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom